Fat mass and obesity-associated protein attenuates lipid accumulation in macrophage foam cells and alleviates atherosclerosis in apolipoprotein E-deficient mice
Authors:
- Ming YangMing Yang
- Xiaojuan HanXHXiaojuan Han
- Junhong LiJLJunhong Li
- Guangping GaoGGGuangping Gao
- Haoran TaiHTHaoran Tai
- Ning HuangNHNing Huang
- Hengyi XiaoHXHengyi Xiao
- 1 April 2017
- journal article
- research article
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 35 (4) , 810-821
Abstract
Genome-wide association studies have linked variants of fat mass and obesity-associated protein (FTO) to obesity. However, the molecular function of FTO remains unclear. In this study, we sought to investigate the potential effects of FTO in modulating cholesterol deposition in macrophage foam cells, as well as whether FTO exerts antiatherosclerotic properties in apolipoprotein E-deficient mice. We transfected RAW264.7 cells with plasmids encoding a wild-type or mutant FTO gene (I367F). The upregulation of FTO markedly attenuated cholesterol ester accumulation in macrophages loaded with oxidized LDL, whereas the downregulation of FTO reversed this effect. Moreover, FTO attenuated the mRNA and protein expression of a scavenger receptor, CD36, which was accompanied by the decline of peroxisome proliferator-activated receptor γ protein. In addition, FTO enhanced the phosphorylation of AMP-activated protein kinase (AMPK)α and acetyl-CoA carboxylase, which was effectively suppressed by FTO small interfering RNA. Pretreatment with compound C or transfection with a dominant-negative AMPKα blocked the FTO-mediated upregulation of ATP-binding cassette transporter A1 and ATP-binding cassette transporter G1. Furthermore, FTO suppressed IL-1β secretion independent of the activation of the nucleotide-binding oligomerization domain-like receptor family pyrin domain containing 3 inflammasome. In-vivo experiments were performed using apolipoprotein E-deficient mice that were infected with adeno-associated virus serotype 9-derived vectors encoding a wild-type or mutant FTO gene. FTO overexpression prevented the formation of atherosclerotic plaques and markedly reduced the content of plasma total cholesterol and LDL cholesterol. Notably, the antiatherosclerotic properties of FTO were observed only in male mice. We propose that the FTO-dependent control of cholesterol deposition may provide avenues for the treatment of atherosclerosis.Keywords
This publication has 44 references indexed in Scilit:
- Initiation and perpetuation of NLRP3 inflammasome activation and assemblyImmunological Reviews, 2015
- Mechanisms of Chronic State of Inflammation as Mediators That Link Obese Adipose Tissue and Metabolic SyndromeMediators of Inflammation, 2013
- Atherosclerosis as an Inflammatory DiseaseCurrent Pharmaceutical Design, 2012
- NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystalsNature, 2010
- Effects of Native and Modified Low-Density Lipoproteins on Monocyte Recruitment in AtherosclerosisHypertension, 2007
- Cytokines in Atherosclerosis: Pathogenic and Regulatory PathwaysPhysiological Reviews, 2006
- Macrophages in InflammationCurrent Drug Targets - Inflammation & Allergy, 2005
- Macrophage Activation in Atherosclerosis: Pathogenesis and Pharmacology of Plaque RuptureCurrent Vascular Pharmacology, 2005
- Oxidized low density lipoprotein and innate immune receptorsCurrent Opinion in Lipidology, 2003
- Scavenger Receptors Class A-I/II and CD36 Are the Principal Receptors Responsible for the Uptake of Modified Low Density Lipoprotein Leading to Lipid Loading in MacrophagesJournal of Biological Chemistry, 2002